IngredientsStreptococcus oralis is the formal scientific name of this bacterium. It belongs to the domain Bacteria, phylum Firmicutes, class Bacilli, order Lactobacillales, family Streptococcaceae, and genus Streptococcus. It is a Gram-positive viridans streptococcus belonging to the Streptococcus mitis group. Its closest phylogenetic relatives include S. mitis, S. pneumoniae, and S. pseudopneumoniae. These species exhibit greater than 99% 16S rRNA sequence identity and are difficult to differentiate using conventional biochemical tests.
Streptococcus oralis is a Gram-positive, nonmotile, alpha-hemolytic bacterium and one of the most abundant commensal bacteria in the human oral cavity, considered to be an early colonizer of dental plaque. It belongs to the Mitis group of streptococci. S. oralis is catalase negative and oxidase negative. Strains of S. oralis produce neuraminidase and cannot bind α-amylase. S. oralis is also acid-sensitive, producing alkaline metabolites to ameliorate its niche.
S. oralis is a numerically important member of the commensal oral microbiota, isolated from all intra-oral surfaces and a pioneer organism involved in the primary colonization of the dentition. It is one of the pioneer species associated with eubiotic dental pellicle biofilms and can be found in high numbers on most oral surfaces. In addition to the oral cavity, S. oralis can colonize genitourinary organs, including the vaginal canal.
In the context of dietary supplementation, S. oralis is used exclusively as a live bacterial probiotic preparation. It is not a botanical or chemical extract. It is a member of the normal human oral microbiota and is capable of opportunistic pathogenicity; like related oral streptococci, it exhibits appreciable phenotypic and genetic variation. The genome of the well-characterized reference strain, S. oralis 34 (1,920,884 bp; GC content, 41.3%), is commonly used in many oral microbiology studies exploring bacterial attachment and interaction within mixed-species model systems.
The strains most relevant to supplement use include KJ3 (also designated KJ3sm, a naturally occurring streptomycin-resistant variant) and 89a. S. oralis strain KJ3 was previously designated S. sanguis Type II strain KJ3, reflecting historical reclassification. Compositions used in research can comprise strains ATCC 35037, ATCC 55229, ATCC 700233, ATCC 700234, and ATCC 9811. Other strains include KJ3 and KJ3sm. KJ3sm is a naturally occurring genetic variant of KJ3 that is resistant to streptomycin.
S. oralis is sourced by isolation from the human oral cavity. Plaque samples from healthy gingival sulci typically contain large numbers of viridans streptococci, including S. oralis and S. uberis. The two particular strains used in probiotic research, S. oralis KJ3sm and S. uberis KJ2sm, were isolated from the mouth of a human volunteer and have been extensively characterized.
As a dietary supplement ingredient, S. oralis has been formulated in several delivery forms:
S. oralis is not derived from any botanical or plant source, nor does it have a defined chemical formula — it is a whole, live microorganism. There are no traditional fermented-food preparations in which S. oralis is deliberately concentrated, distinguishing it from many other probiotic species such as lactobacilli found in yoghurt.
Streptococcus oralis does not carry a documented history of traditional or ethnobotanical use by any culture or medical tradition. Unlike fermented food-derived probiotics such as Lactobacillus acidophilus in yoghurt, S. oralis was not knowingly incorporated into any food or medicinal preparation prior to the modern era of microbiology. Its presence in the human oral cavity has been a biological constant throughout human history, but its deliberate study as a probiotic agent is an entirely modern phenomenon rooted in clinical microbiology research.
The earliest reported Streptococcus strains displaying a probiotic benefit were isolated from the subgingival plaque of a healthy adult subject in 1985 (Hillman et al., 1985). This 1985 isolation represents the historical starting point for the investigation of S. oralis as a beneficial or probiotic organism. The concept that followed — that restoration of commensal oral streptococci might counteract pathogenic species — is therefore a late twentieth-century scientific idea rather than a traditional health practice.
The broader framework into which S. oralis fits is the "replacement therapy" or "bacteriotherapy" approach in dentistry: the targeted delivery of beneficial commensal bacteria to restore microbial balance. This paradigm was developed over subsequent decades in academic microbiology and has no equivalent in pre-scientific oral medicine traditions.
Unlike plant-derived supplements, S. oralis does not yield a list of discrete phytochemicals. Its biological activities derive from metabolic by-products and surface properties of the living organism. The principal documented mechanisms are described below.
The mitis group streptococci produce hydrogen peroxide (H₂O₂) as a by-product of aerobic metabolism. Three enzymatic pathways for the generation of H₂O₂ in oral streptococci have been described. Pyruvate oxidase, encoded by the spxB gene, is highly conserved in oral streptococci.
S. oralis strain KJ3 and S. uberis strain KJ2 were shown to have inhibitory effects on the growth of oral pathogens implicated in periodontitis, including Fusobacterium nucleatum, Aggregatibacter actinomycetemcomitans, and Porphyromonas gingivalis. The production of hydrogen peroxide by S. oralis KJ3 and S. uberis KJ2 was found to be the mechanism of action for pathogen growth inhibition.
Deletion mutants of S. oralis lacking the spxB gene, which encodes pyruvate oxidase, and therefore deficient in H₂O₂ production, showed reduced cytotoxicity toward THP-1 macrophages, confirming the central role of this enzyme in the bacterium's biological activity.
The natural viridans streptococcal strains S. oralis (KJ3sm) and S. uberis (KJ2sm) can promote periodontal health by production of hydrogen peroxide, which inhibits the growth of periodontal pathogens. Hydrogen peroxide production is a normal end product of glycolysis when these microorganisms are incubated in the presence of a sugar, such as glucose or sucrose, and there is oxygen present in the atmosphere.
The H₂O₂ generated at low concentrations also has a proposed tooth-whitening effect. Stained dental ceramic material, representative of stained dental enamel, was treated with a suspension of S. oralis to determine if S. oralis can promote tooth whitening. A suspension of S. oralis was incubated in vitro in the presence of glucose and oxygen to determine if it could produce sufficient hydrogen peroxide to enable a measurable whitening effect on stained ceramic disks resembling teeth.
One of the key compounds produced by oral streptococci is hydrogen peroxide (H₂O₂). In mammalian cells, H₂O₂ triggers the activation of nuclear factor erythroid 2-related factor 2 (Nrf2), a key pathway mediating antioxidant defence.
Research aimed to determine whether H₂O₂-producing oral streptococci activated the Nrf2 pathway in macrophages and whether the activation of Nrf2 influenced the innate immune response. The investigators found that oral streptococci downregulated the innate immune response in a H₂O₂-dependent manner through the activation of Nrf2. These results suggest that oral streptococci are likely not passive bystanders but could play an essential role in the maintenance of periodontal health through the prevention of overt inflammation.
S. oralis strains are early colonizers of the tooth surface, binding strongly to the salivary pellicle. This surface adherence property underlies the competitive exclusion mechanism: by occupying binding sites on tooth and mucosal surfaces first, probiotic strains of S. oralis prevent attachment and subsequent colonization by pathogenic species.
Oral streptococci are the pioneer colonisers of the plaque biofilm. In periodontal health, oral streptococci are the dominant species of oral microbiota, constituting between 60 and 80% of the total cultivable microbial flora.
Probiotics S. salivarius 24SMB and S. oralis 89a have been shown to interfere with biofilm formation of pathogens of the upper respiratory tract.
S. oralis is acid-sensitive, producing alkaline metabolites to ameliorate its niche. The production of alkaline end-products helps buffer oral pH, which is a mechanism for resisting the acid-driven dissolution of tooth enamel associated with cariogenic species such as S. mutans. This is a commensal property that mirrors the caries-protective alkaline production well documented in S. dentisani and related species.
Strains of S. oralis produce neuraminidase, an enzyme that cleaves sialic acid residues from glycoproteins. In commensal contexts, this activity may facilitate bacterial adhesion to host mucosal surfaces, supporting colonization and niche maintenance, though its full functional significance in probiotic applications has not been clearly delineated in human studies.
In vitro and early characterization: Two strains, S. oralis strain KJ3 and S. uberis strain KJ2, were shown to have inhibitory effects on the growth of oral pathogens implicated in periodontitis, including Fusobacterium nucleatum, Aggregatibacter actinomycetemcomitans, and Porphyromonas gingivalis. The production of hydrogen peroxide by S. oralis KJ3 and S. uberis KJ2 was found to be the mechanism of action for pathogen growth inhibition. These findings, reported by Hillman et al. in 1985, established the foundational rationale for S. oralis KJ3 as an oral probiotic candidate.
Pilot human clinical trial (ProBiora3 mouthwash, 2009): A pilot human clinical trial was conducted to assess the safety and ability of a probiotic mouthwash, ProBiora3, to affect the levels of S. mutans and certain known periodontal pathogens when administered twice daily over a period of 4 weeks. The mouthwash was tested at two dose levels: 10⁶ and 10⁸ colony forming units each of S. oralis strain KJ3sm, S. uberis strain KJ2sm, and the spontaneous lactic acid-deficient variant of S. rattus, strain JH145. Substantial decreases in the levels of the marker bacteria were observed. No safety issues were noted with the twice daily application of this mouthwash. The investigators noted the pilot nature of the study and its small sample size as important limitations.
Randomized controlled trial in periodontitis patients (2015): A randomized controlled trial evaluated the adjunctive effects of a S. oralis KJ3, S. uberis KJ2, and S. rattus JH145-containing probiotic tablet after scaling and root planing (SRP). Forty-eight periodontitis patients were included in this double-blind, placebo-controlled clinical trial. After root planing, patients used either a placebo or a probiotic tablet twice a day for 12 weeks. The primary and secondary outcome measures were significantly improved at the 12- and the 24-week evaluation in both groups. However, no significant inter-group differences could be detected at any time point, except for the percentage of sites with plaque, which were significantly lower in the probiotic group.
This is the most methodologically rigorous human clinical trial specifically involving S. oralis KJ3 in a periodontal indication. The result is sobering: clinical improvement occurred in both groups following professional treatment (SRP), and the probiotic did not demonstrate superior benefit over placebo on the primary periodontal clinical outcome measures. The evidence for S. oralis KJ3 as an adjunct to SRP in chronic periodontitis is therefore currently weak based on available RCT data.
Of the probiotic genera for oral health, Streptococcus spp. have the strongest support for health benefits in the oral cavity, including reducing the incidence of caries, reducing levels of halitosis-causing bacteria, improving oral pH, and whitening teeth. However, much of this evidence applies to the genus broadly, and the specific evidence for strain KJ3 in dental caries is limited largely to in vitro and pilot human data.
The ProBiora3 mouthwash pilot trial (Zahradnik et al., 2009) demonstrated a reduction in salivary S. mutans levels — the primary cariogenic organism — in orally healthy adults. Despite the small number of subjects and the use of young, orally healthy adults, along with the inherent variability in the microbiological measurements, the probiotic mouthwash was able to substantially affect the levels of dental pathogens in saliva. The results suggest that the probiotic mouthwash product may be safe for daily use as an aid in maintaining dental and periodontal health. No long-term caries incidence data from RCTs with S. oralis KJ3 are available in the reviewed literature. Evidence in this area is preliminary.
An in vitro investigation demonstrated that S. oralis KJ3sm can produce sufficient H₂O₂ in the presence of sugar and oxygen to cause measurable whitening on stained dental ceramic disks. The makers of ProBiora3 report that in laboratory studies, the low-dose hydrogen peroxide produced by S. oralis KJ3 created a whitening benefit that continued to improve over the duration of the study. As this bacterium is replenished daily, it creates gradual whitening with the full benefits of long contact times. No independent, peer-reviewed human RCT examining tooth whitening as a primary endpoint for S. oralis was identified in the available literature. Evidence is in vitro only.
Randomized placebo-controlled clinical study (2019): Group A beta-hemolytic Streptococcus (GABHS) causes recurrent acute pharyngotonsillitis (RAPT) in children, and the repeated use of antibiotics contributes to its resistance. Patients with microbiologically confirmed GABHS were enrolled in this randomized, placebo-controlled trial. They received the aforementioned combination or placebo as an oral spray. The investigators examined episodes of frequency and duration, need for antibiotics, school days lost, treatment impact on quality of life, treatment compliance, and side effects during a 90-day treatment and a 6-month follow-up. Forty-one patients were included in each group. The mean number of GABHS infections was significantly lower during both study periods for both groups. The investigators identified potential probiotics possessing desirable features against GABHS pharyngotonsillitis and described the findings as the first evidence that these probiotics can reduce antibiotic use.
Dose and design details: The study administered S. salivarius 24SMB and S. oralis 89a as an oral spray; the active suspension consisted of a minimum of 125 × 10⁹ CFU/mL in 10 mL of saline; the control was a matched placebo of 2 puffs once a day, with an oral spray providing 2 × 10⁹ CFU per puff, for 3 months. All study participants were compliant to the assigned intervention (>80% compliance). Only four study participants reported an adverse event — three in the probiotic group and one in the control group.
The evidence in this area is promising but preliminary. The trial enrolled only a moderate number of children and was not blinded with respect to treatment assignment in all reports of this research line. Replication and larger independent trials are needed.
Uncontrolled observational study in 202 children (2019): Nasal administration of S. salivarius 24SMB and S. oralis 89a was evaluated in 202 children with a recent diagnosis of recurrent upper respiratory tract infection. All patients were treated twice daily for 7 days each month for 3 consecutive months with a nasal spray. Evaluation was performed at the end of treatment and at follow-up at 3, 6, and 12 months. Patients who completed the entire 90-day course of bacteriotherapy and the follow-up period showed a 64.3% reduction in their episodes of upper respiratory tract infections compared to baseline. Prophylactic bacteriotherapy by administration of S. salivarius 24SMB and S. oralis 89a in children with a history of recurrent upper respiratory tract infection was concluded to potentially reduce the number of episodes of otolaryngologic infections. Importantly, this study lacked a concurrent placebo-controlled arm, limiting its interpretability.
Pilot study on short-term efficacy (2020): Children treated with S. salivarius 24SMB and S. oralis 89a showed a significant decrease of symptoms including episodes of fever, cough, bronchospasm, rhinorrhea, and otalgia (p < 0.001) compared to baseline. This was a pilot study without a concurrent randomized placebo group.
Adenoidal disease intervention: A prospective, double-blind, randomized controlled study assessed the efficacy and safety of the topical nasal administration of a probiotic compound based on S. salivarius 24SMB and S. oralis 89a in children with adenoidal disease, targeting reduction in acute adenoidal infections and blockage of nasopharynx space by hypertrophic adenoids. It was carried out at the University of Milan's Department of Clinical Sciences and Community Health between January 2019 and January 2021.
The overall evidence base in this area is promising but methodologically weak. A number of studies lack proper placebo controls or are small observational investigations. Firm conclusions about efficacy for URTIs or otitis media await adequately powered, placebo-controlled, blinded RCTs.
Probiotic benefits are highly strain-specific. Many bacterial species and strains used in probiotic products marketed for oral care have no documented benefit in the oral cavity and are used based on a history of safe use, rather than efficacious use. This principle is critical when interpreting claims made for any individual S. oralis product.
The following dosages are reported directly from peer-reviewed or registered clinical sources; they are presented as historical research data only and not as recommended doses.
The three bacterial species used in the ProBiora3 formulation are known to be normal colonizers of the human mouth and, as such, address a major issue for successful application as a probiotic for use in improving oral and dental health. No treatment-related adverse effects were observed in physiological parameters during the 14-week rat study, or in the evaluation of blood and tissue samples taken from the animals at the end. Results of an in vitro antibiotic susceptibility study demonstrate that all three ProBiora3 strains are susceptible to commonly used therapeutic antibiotics.
No safety issues were noted with the twice daily application of the ProBiora3 mouthwash in the pilot human trial. In the S. oralis 89a pharyngotonsillitis study, only four study participants reported an adverse event — three in the probiotic group and one in the control group.
A series of clinical trials investigating the preventive role of local bacteriotherapy demonstrated that bacteriotherapy safely reduced the prevalence and severity of respiratory infections, the use of antibiotics, and absences from school.
This is the most significant and source-backed safety concern associated with S. oralis. The infection most associated with S. oralis is infective endocarditis. S. oralis is frequently isolated from cases of infective endocarditis.
The viridans group streptococci (VGS) comprise a diverse collection of alpha and non-hemolytic streptococci that inhabit the oral cavity and gastrointestinal and genitourinary tracts of healthy humans. VGS are also associated with invasive disease, particularly in immunocompromised hosts, and are estimated to cause approximately 23% of Gram-positive bacteremia and approximately 17% of infective endocarditis (IE) cases.
The rate of bacteremia caused by members of the mitis group of streptococci is comparable to that caused by group A or group B streptococci. S. oralis and S. mitis are recognized as important aetiological agents of subacute bacterial endocarditis and septicaemia in neutropenic cancer patients. This pathogenic potential is intrinsic to S. oralis as a species and is independent of specific probiotic strain designations.
The significance of this for supplement use is that S. oralis should be regarded with caution in individuals with structural cardiac defects, prosthetic heart valves, immunocompromise, or neutropenia. In 2007, the American Heart Association changed their recommendations to ongoing prophylaxis only for those patients at highest risk of developing IE (those with history of infective endocarditis, prosthetic valves, cardiac transplantation who develop cardiac valvulopathy, and congenital heart disease). This population overlaps with those for whom deliberate oral administration of viridans streptococci warrants particular caution.
Results of an in vitro antibiotic susceptibility study demonstrate that all three ProBiora3 strains — including S. oralis KJ3 — are susceptible to commonly used therapeutic antibiotics. This is a favorable safety characteristic, as it means that in the event of inadvertent infection in a susceptible individual, standard antibiotic treatments would remain effective.
In contrast, some clinical S. oralis strains isolated from patients with infections have shown antibiotic resistance. Genes involved in macrolide and tetracycline resistance, namely ermB and tet(M), and mutations in penicillin-binding proteins have been identified in clinical isolates of S. oralis. The resistance profile of probiotic supplement strains may differ from clinical pathogenic isolates, but this underscores the general importance of strain-level characterization.
S. oralis shows high genetic diversity and is competent for natural genetic transformation. S. oralis cells are able to take up exogenous DNA and incorporate exogenous sequence information into their genomes by homologous recombination. Analysis of S. oralis isolates characterizes the population as highly diverse and undergoing inter- and intra-species recombination. The potential for horizontal gene transfer, including transfer of resistance genes, is a theoretical long-term concern in repeated supplementation contexts, though this has not been studied in clinical probiotic settings.
Probiotic benefits are highly strain-specific. Many bacterial species and strains used in probiotic products marketed for oral care have no documented benefit in the oral cavity and are used based on a history of safe use, rather than efficacious use. This principle applies directly to S. oralis: the body of evidence, while mechanistically coherent and encouraging in early clinical investigations, remains insufficient to draw firm conclusions about population-level benefits, and the species' well-documented capacity for opportunistic infection in vulnerable hosts demands strain-specific, indication-specific, and patient-specific evaluation before broad supplementation recommendations can be made.
Health conditions that Streptococcus oralis may help support.
Body systems that Streptococcus oralis may help support.
Go back